25 February 2019 - A line of defence is emerging for top prescription drug companies whose top executives will be pulled before Congress on Tuesday to testify about high prices for medicine: They are not to blame.

It’s a corporate version of a “devil made me do it’’ argument.

The industry says it is trapped in a reimbursement system that has become badly distorted, one that rewards companies for jacking up list prices and then offering deep discounts, in the form of rebates, to win favourable treatment by insurance plans.

Read Washington Post article